Kirti Desai
Plus aucun poste en cours
Fortune : 8 M $ au 31/05/2024
Postes actifs de Kirti Desai
Sociétés | Poste | Début | Fin |
---|
Historique de carrière de Kirti Desai
Anciens postes connus de Kirti Desai
Sociétés | Poste | Début | Fin |
---|---|---|---|
Tevogen Bio, Inc.
Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Directeur/Membre du Conseil | - | - |
Directeur Financier/CFO | 01/06/2020 | - |
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director of Finance/CFO | 2 |
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Tevogen Bio, Inc.
Tevogen Bio, Inc. BiotechnologyHealth Technology Tevogen Bio, Inc. is a late-stage biotech company based in Warren, NJ. Tevogen Bio is focused on developing accessible personalized immunotherapies using its pioneering technology, the exactcelltm platform, which produces scalable, rapidly available, unmodified allogeneic cytotoxic T lymphocytes (CTLs) for the treatment of cancers, viral infections, and the prevention of long-term complications of these conditions. Tevogen Bio's strategic partners share their values and mission, and their next-generation precision T cell platform is designed to provide increased specificity to eliminate malignant and virally infected cells while allowing healthy cells to remain intact. The company is committed to pioneering lifesaving innovations for viral diseases and cancers for which there is a high unmet need. The company was founded in 2020 by Ryan Saadi, who has been the CEO since then. | Health Technology |
- Bourse
- Insiders
- Kirti Desai
- Expérience